Mass Spectrometry-Based Multiplexing for the Analysis of Biomarkers in Drug Development and Clinical Diagnostics- How Much is too Much?
about
Proteomics and metabolomics in renal transplantation-quo vadis?Biomarkers in Transplantation--Proteomics and Metabolomics.A Combination of DNA-peptide Probes and Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS): A Quasi-Targeted Proteomics Approach for Multiplexed MicroRNA Quantification.The advantages of microflow LC-MS/MS compared with conventional HPLC-MS/MS for the analysis of methotrexate from human plasma.Amino acids in a targeted versus a non-targeted metabolomics LC-MS/MS assay. Are the results consistent?
P2860
Mass Spectrometry-Based Multiplexing for the Analysis of Biomarkers in Drug Development and Clinical Diagnostics- How Much is too Much?
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Mass Spectrometry-Based Multip ...... nostics- How Much is too Much?
@ast
Mass Spectrometry-Based Multip ...... nostics- How Much is too Much?
@en
type
label
Mass Spectrometry-Based Multip ...... nostics- How Much is too Much?
@ast
Mass Spectrometry-Based Multip ...... nostics- How Much is too Much?
@en
prefLabel
Mass Spectrometry-Based Multip ...... nostics- How Much is too Much?
@ast
Mass Spectrometry-Based Multip ...... nostics- How Much is too Much?
@en
P2093
P2860
P1476
Mass Spectrometry-Based Multip ...... nostics- How Much is too Much?
@en
P2093
Jacek Klepacki
Jelena Klawitter
Jost Klawitter
Touraj Shokati
Uwe Christians
P2860
P356
10.1016/J.MICROC.2012.02.011
P577
2012-11-01T00:00:00Z